liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Överlevnaden vid maligna gliom har ökat senaste tio åren - Analys av kvalitetsregisterdata: [Survival in malignant gliomas has increased the last decade. Analysis of quality data]
Cancercentrum, Norrlands universitetssjukhus, Umeå.
Umeå universitet.
Linköping University, Department of Clinical and Experimental Medicine, Cell Biology. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, LAH Linköping.
Akademiska sjukhuset, Uppsala .
Show others and affiliations
2012 (Swedish)In: Läkartidningen, ISSN 0023-7205, Vol. 109, no 17-18, 875-878 p.Article in journal (Refereed) Published
Abstract [sv]

Den årliga incidensen av hög­maligna gliom, WHO grad III–IV, i Sverige är ungefär 400.

Medianöverlevnaden för höggradiga gliom har ökat från 8,1 månader till 10,0 månader under det senaste decenniet i en ose­lekterad svensk population.

För åldersgruppen 60–69 år har medianöverlevnaden ökat från 5,8 månader till 10,5 månader under denna period, dvs nästan en fördubbling.

Utveckling av befintliga behandlingsmetoder, nya behandlingsstrategier och en mer aktiv inställning till terapi har sannolikt bidragit till de beskrivna överlevnads­vinsterna.

Abstract [en]

The annual incidence rate of high grade malignant glioma (WHO grade III-IV) in Sweden is approximately 400 patients. The objective for the Swedish National CNS-tumor Group is to lay a foundation for research efforts and facilitate implementation and assessment of therapeutic strategies and health care for this patient group. In the analyses the diagnoses of high grade malignant gliomas are compared for the years 1999-2003, 2004-2006 and 2007-2009 for the Northern Region, the Uppsala Region and the South-east Region of Sweden, a population of 1844 patients. Survival was estimated from Kaplan-Meier survival curves, and a log-rank test was performed to assess whether the survival curves differed. The crude hazard ratio between years of diagnosis was estimated from a Cox regression model. Median survival for all patients 2004-2006 was 10.0 months (95 % confidence interval (CI) 8.9-10.9) compared to 8.1 months 1999-2003 (95 % CI 7.3-8.8). For patients 60-69 years of age almost a doubling of the survival rate has occurred during the last decade. Medan survival has increased from 5.8 months (95 % CI 5.1-7.5) 1999-2003 to 8.5 months (95 % CI 7.0-10.3) for 2004-2006 and to 10.5 months (95 % CI 9.0-12.6) for 2007-2009. Concomitant radiochemotherapy, but also the development of neurosurgical and radiotheraputic techniques and a more active therapeutic attitude, including the older patient groups, have probably contributed to the improved survival rate. A national population based registry, with a close to 100% registration compliance for important diagnostic and outcome parameters is probably an efficient instrument for evaluation of quality measures and implementation of new therapeutic strategies.

Place, publisher, year, edition, pages
Läkartidningen Förlag , 2012. Vol. 109, no 17-18, 875-878 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-89958PubMedID: 22642054OAI: diva2:610584
Available from: 2013-03-12 Created: 2013-03-12 Last updated: 2013-03-21

Open Access in DiVA

No full text

Other links

PubMedLänk till artikel

Search in DiVA

By author/editor
Malmström, Annika
By organisation
Cell BiologyFaculty of Health SciencesLAH Linköping
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 78 hits
ReferencesLink to record
Permanent link

Direct link